Article Information
History
- April 12, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Zahra Sadouki1,2,⍰,
- Emmanuel Q. Wey2,3,⍰,*,
- Sateesh Iype4,
- David Nasralla4,
- Jonathan Potts5,
- Mike Spiro6,7,
- Alan Williams8,
- Timothy D. McHugh2 and
- Frank Kloprogge1
- 1Institute for Global Health, University College London, UK
- 2Centre of Clinical Microbiology, University College London, UK
- 3Department of Infection, Royal Free London NHS Trust, UK
- 4Department of HPB and Liver Transplant Surgery Royal Free Hospital
- 5Department of Hepatology, Sheila Sherlock Liver Unit, Royal Free London
- 6Department of Surgical biotechnology, UCL
- 7Department of Intensive care medicine Royal Free London
- 8Department of Infection Sciences, Health Services Laboratories, London, UK
- ↵*Corresponding author:
Dr Emmanuel Wey, Department of Infection, Consultant and Honorary Associate Professor in Infection, Royal Free London NHS Trust, Centre for Clinical Microbiology, Division of Infection & Immunity, University College London, emmanuel.wey{at}nhs.net
↵⍰ Both authors contributed equally
Authors contribution statement: All authors contributed to the inception and planning of the work. ZS ⍰ and EW⍰ wrote the manuscript and contributed equally, and all authors edited.
Posted April 12, 2024.
Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)
